Enters into Worldwide Collaboration with Bayer to Market and Develop
Novel Therapies for Cardiovascular Disease
Collaboration Includes a
The company also announced a worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators. This includes Bayer’s Adempas® (riociguat), the first member of this novel class of compounds. Adempas is approved to treat pulmonary arterial hypertension (PAH) and is the first and only drug treatment approved for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Adempas is currently marketed in
“The sale of our consumer care business is part of our efforts to ensure that assets within our portfolio align with our core strategy, have industry-leading potential and generate long-term shareholder value,” said
"Merck Consumer Care is a strong business with a portfolio of well-established product brands, such as Claritin, Afrin and Coppertone®, that are leaders in their respective categories," said Dr.
The collaboration also includes clinical development of vericiguat (BAY102), which is currently in Phase 2 trials for worsening heart failure, as well as opt-in rights for other early-stage sGC compounds in development at Bayer. Merck will in turn make available its early-stage sGC compounds under similar terms.
In return for these broad collaboration rights, Bayer will receive a
Merck expects after-tax proceeds from the sale of MCC to be between
“Both Merck and Bayer have a rich history of developing and commercializing innovative products to meet significant unmet medical needs,” said Frazier. “Our collaboration with Bayer builds on our respective strengths, and we look forward to working with Bayer in the field of sGC modulators.
“The value we obtained for our consumer business is a tribute to our colleagues who have built an outstanding business with a talented team and trusted, well-known product brands,” said Frazier. “We know the strengths of our team will serve Bayer well.”
Merck expects to close the sale of MCC in second half of 2014, subject to customary closing conditions, including regulatory approvals. The company plans to update its 2014 financial guidance when the transaction closes.
Morgan Stanley & Co. LLC acted as financial advisor to Merck, and
Conference Call and Webcast
Merck will hold an Investor Briefing today at
There will be a live webcast of the event available on Merck's website at www.merck.com. Software needed to listen to the webcast may be obtained on the corporate website and should be downloaded prior to the beginning of the webcast. Institutional investors, analysts and members of the media also can participate by dialing (706) 634-2289 or (877) 214-9289 and using ID code number 42688075.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2013, the Group employed 113,200 people and had sales of €40.2 billion. Capital expenditures amounted to €2.2 billion, R&D expenses to €3.2 billion. For more information, go to www.bayer.com.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the